8-K: Novavax Outlines Strategy at TD Cowen Conference, Focuses on Partnerships and R&D

Novavax is shifting its focus towards research and development and strategic partnerships, particularly with Sanofi, to drive future growth and value creation.

Summary

• Novavax presented an update at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, outlining its corporate strategy and operating plans.
• The company is focusing on building a company based upon scientific expertise in vaccines and its proven technology platform.
• A key element of the strategy is leveraging partnerships, particularly the collaboration with Sanofi, to commercialize its COVID-19 vaccine and develop combination vaccines.
• Novavax is also advancing its technology platform and early-stage pipeline, including a COVID-19-Influenza Combination (CIC) vaccine and a stand-alone flu program.
• The company is establishing a lean operating model to drive shareholder value, targeting a long-term core spend profile of $250 million when adjusted to remove CIC investment and Sanofi support.
• Novavax expects significant operating cost savings beginning in 2025, with a reduction of over $170 million from ending its lead commercialization role and ~$80 million from the sale of its Czech Republic manufacturing facility.
• Full year 2025 guidance for combined R&D and SG&A expenses is $475 $525 million, with approximately 70% of the spend in R&D.
• The company anticipates potential revenue from Sanofi royalties, CIC and Matrix-M related milestones, and Nuvaxovid product sales, but these are not included in the 2025 revenue framework.
• Novavax is eligible to receive up to $350 million in Phase 3 development and commercial launch milestone payments associated with Sanofi influenza-COVID-19 combination products.
• For each new vaccine using Matrix-M, Novavax is eligible to receive up to $200 million in launch and sales milestones and mid-single digit royalties for 20 years.

Sentiment

Score: 7

Explanation: The document presents a strategic shift with potential for long-term growth, driven by partnerships and R&D. While there are risks and uncertainties, the overall tone is positive, reflecting confidence in the company's future prospects.

Positives

• The Sanofi partnership provides multiple potential revenue streams, including upfront payments, milestones, royalties, and cost reimbursement.
• Novavax's Matrix-M adjuvant has shown promise in inducing stronger and longer-lasting immune responses.
• The company is actively partnering Matrix-M with vaccine companies to improve existing portfolios and bring new vaccines to market.
• Novavax has initiated a Phase 3 clinical trial for its COVID-19 and influenza combination vaccine.
• The company is reducing operating expenses to enable value creation.
• Novavax has a diversified vaccine pipeline, including candidates for COVID-19, influenza, RSV, shingles, and C. difficile.
• The R21/Matrix-M malaria vaccine, developed with Oxford University and Serum Institute of India, has received WHO authorization and is being used in multiple African countries.

Negatives

• Novavax is reliant on Sanofi's sales forecasts to estimate royalties, which are not included in the full year 2025 guidance.
• The company faces challenges in obtaining regulatory authorization for its COVID-19 vaccine, particularly with respect to its BLA submission to the FDA.
• Novavax is dependent on Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for co-formulation and filling its COVID-19 vaccine.
• The company faces challenges in meeting contractual requirements under agreements with multiple commercial, governmental, and other entities.
• There are challenges related to the seasonality of vaccinations against COVID-19 or influenza.
• Novavax's expectations as to expenses and cash needs may prove not to be correct due to changes in plans or actual events being different than its assumptions.

Risks

• Challenges or delays in obtaining regulatory authorization for its COVID-19 vaccine.
• Challenges related to Novavax's partnership with Sanofi and in pursuing additional partnership opportunities.
• Manufacturing, distribution, or export delays or challenges.
• Difficulty obtaining scarce raw materials and supplies, including for its proprietary adjuvant.
• Constraints on Novavax's ability to pursue planned regulatory pathways, alone or with partners.
• Challenges in implementing its global restructuring and cost reduction plan.
• Challenges in obtaining commercial adoption and market acceptance of its updated 2024-2025 formula COVID-19 vaccine or any COVID-19 variant strain containing formulation.
• Challenges related to the demand for vaccinations against COVID-19 or influenza.

Future Outlook

Novavax anticipates additional Sanofi-related milestones, data from late-stage assets, additional and enhanced partnerships, and advancement of its early-stage pipeline in 2025 and beyond.

Management Comments

• John C. Jacobs, President and Chief Executive Officer: 'Our strategy is focused on building a company based upon our scientific expertise in vaccines and our proven technology platform to achieve our ambition of tackling some of the worlds most pressing health challenges.'
• Elaine OHara, Executive Vice President and Chief Strategy Officer: 'Our partnership with Sanofi sets the bar for what is possible when our novel technology platform is combined with others world class commercialization capabilities.'
• Jim Kelly, Executive Vice President, Chief Financial Officer and Treasurer: 'We remain focused on improving the financial strength and performance of Novavax to drive shareholder value.'

Industry Context

The announcement reflects a broader trend in the vaccine industry towards strategic partnerships and collaborations to leverage complementary strengths and accelerate product development and commercialization. Novavax's partnership with Sanofi is a significant move in this direction, allowing Novavax to focus on its core competencies in R&D while leveraging Sanofi's commercial infrastructure.

Comparison to Industry Standards

• Novavax's Matrix-M adjuvant is comparable to other adjuvants like GSK's AS03 and AS01 in terms of enhancing immune responses.
• The company's COVID-19 vaccine competes with mRNA vaccines from Pfizer and Moderna, as well as other protein-based vaccines.
• The development of a COVID-19-Influenza Combination (CIC) vaccine is in line with industry efforts to simplify vaccination schedules and improve patient compliance, similar to efforts by other major vaccine manufacturers.
• Novavax's focus on a lean operating model is a common strategy among biotech companies to manage costs and improve profitability, comparable to restructuring efforts undertaken by companies like Biogen and Amgen.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through partnerships and R&D.
• Employees: Restructuring and cost reduction may impact workforce.
• Customers: Access to innovative vaccines through partnerships.
• Suppliers: Potential changes in supply chain due to manufacturing facility sale.
• Creditors: Improved financial stability through cost reduction and revenue diversification.

Next Steps

• Obtain U.S. COVID-19 BLA approval.
• Initiate Sanofi CIC Phase 3 trial.
• Transition U.S. and EU markets to Sanofi.
• Advance early-stage pipeline programs.
• Pursue additional partnerships.

Key Dates